$RenovoRx (RNXT.US)$ RenovoRx Highlights Promising Pharmacokinetic Data Abstract Presented at ASCO GI 2025 Monday, 27th January at 8:00 am Abstract was presented by TIGeR-PaC Phase III clinical trial Investigator, Paula Novelli, MD, from the University of Pittsburgh Medical Center Sub-study of the pivotal Phase III TIGeR-PaC clinical trial offers insight that supports the potential effectiveness of RenovoRx's TAMP therapy platform in locally advanced pancreatic cancer PK data shows intra-a...
$RenovoRx (RNXT.US)$ RenovoRx Initiates Patient Enrollment at SCRI Oncology Partners for Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial in Locally Advanced Pancreatic Cancer 11 minutes ago, 5:00 AM PST Via GlobeNewswire RNXT Share TIGeR-PaC is Evaluating the TAMP™ (Trans-Arterial Micro-Perfusion) Therapy Platform for the Treatment of Locally Advanced Pancreatic Cancer Dr. Meredith Pelster, Associate Director for GI Research Across Sarah Cannon Research Institute (SCRI), Appointed Princi...
$RenovoRx (RNXT.US)$ RenovoRx Receives First Purchase Orders for its FDA-Cleared RenovoCath® Delivery System Thursday, 5th December at 8:00 am Over Ten Medical Institutions Nationwide have Initiated RenovoCath Purchase Process, Further Accelerating Commercialization Strategy RenovoRx Estimates Initial Target Market Size for RenovoCath of Several Hundred Million Dollars in Annual Sales Global Medical Device Commercial Leader, Richard Stark, Joining RNXT as Commercial Advisor LOS ALTOS, Cal...
$RenovoRx (RNXT.US)$ Northwell Health Cancer Institute Launches Patient Enrollment in RenovoRx's Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial 5 minutes ago, 5:45 AM PST Via GlobeNewswire The Northwell Health Cancer Institute is the Most Recent Clinical Site to Join the TIGeR-PaC Study, and RenovoRx Aims to Reach Full Patient Enrollment in the First Half of 2025 Phase III Clinical Trial is Evaluating the TAMP™ (Trans-Arterial Micro-Perfusion) Therapy Platform for the Treatment of Loc...
$RenovoRx (RNXT.US)$ RenovoRx Announces Presentation at Symposium on Clinical Interventional Oncology Highlighting TAMP™ for Targeted Treatment of Locally Advanced Pancreatic Cancer LOS ALTOS, Calif., Sept. 19, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced that Ripal Gandhi, M.D., FSIR, FSVM will present at the...
1
Report
No comment yet
Sign in to post a comment
Market Insights
U.S. Crypto Concept Stocks U.S. Crypto Concept Stocks
Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data. Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data.
RenovoRx Stock Forum
RenovoRx's Breakthrough Cancer Drug Delivery System Shows Promise in New Pre-Clinical Data
Can RenovoRx's Premium-Priced Cancer Device Deliver on its $400M Market Potential?
Revolutionary Cancer Drug Delivery System: RenovoRx's TAMP Platform Shows Breakthrough Results
RenovoRx Highlights Promising Pharmacokinetic Data Abstract Presented at ASCO GI 2025
Monday, 27th January at 8:00 am
Abstract was presented by TIGeR-PaC Phase III clinical trial Investigator, Paula Novelli, MD, from the University of Pittsburgh Medical Center
Sub-study of the pivotal Phase III TIGeR-PaC clinical trial offers insight that supports the potential effectiveness of RenovoRx's TAMP therapy platform in locally advanced pancreatic cancer
PK data shows intra-a...
RenovoRx Initiates Patient Enrollment at SCRI Oncology Partners for Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial in Locally Advanced Pancreatic Cancer
11 minutes ago, 5:00 AM PST
Via GlobeNewswire
RNXT
Share
TIGeR-PaC is Evaluating the TAMP™ (Trans-Arterial Micro-Perfusion) Therapy Platform for the Treatment of Locally Advanced Pancreatic Cancer
Dr. Meredith Pelster, Associate Director for GI Research Across Sarah Cannon Research Institute (SCRI), Appointed Princi...
RenovoRx Receives First Purchase Orders for its FDA-Cleared RenovoCath® Delivery System
Thursday, 5th December at 8:00 am
Over Ten Medical Institutions Nationwide have Initiated RenovoCath Purchase Process, Further Accelerating Commercialization Strategy
RenovoRx Estimates Initial Target Market Size for RenovoCath of Several Hundred Million Dollars in Annual Sales
Global Medical Device Commercial Leader, Richard Stark, Joining RNXT as Commercial Advisor
LOS ALTOS, Cal...
RNXT SMA200 is $1.20, if we can hold above , that's bullish for sure IMO
But always have that protection in place for the profits !
MORE INFO BELOW 👇
https://chartingdaily.com/delivering-therapy-where-it-matters-now
Communicated disclaimer
Northwell Health Cancer Institute Launches Patient Enrollment in RenovoRx's Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial
5 minutes ago, 5:45 AM PST
Via GlobeNewswire
The Northwell Health Cancer Institute is the Most Recent Clinical Site to Join the TIGeR-PaC Study, and RenovoRx Aims to Reach Full Patient Enrollment in the First Half of 2025
Phase III Clinical Trial is Evaluating the TAMP™ (Trans-Arterial Micro-Perfusion) Therapy Platform for the Treatment of Loc...
RenovoRx Announces Presentation at Symposium on Clinical Interventional Oncology Highlighting TAMP™ for Targeted Treatment of Locally Advanced Pancreatic Cancer
LOS ALTOS, Calif., Sept. 19, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced that Ripal Gandhi, M.D., FSIR, FSVM will present at the...
No comment yet